CD36: A Multifaceted Regulator in the Development and Progression of Atherosclerosis with ANT BIO PTE. LTD.’s Research Tools

1. Concept

CD36, an 88 kDa transmembrane glycoprotein belonging to the class B scavenger receptor family, is encoded by a gene located on human chromosome 7 (7q11.2). Its structure features two transmembrane domains, short cytoplasmic tails, and a large glycosylated extracellular domain—assembled from a 472-amino-acid polypeptide chain. The functional activity of CD36 is tightly regulated by a network of post-translational modifications, including ubiquitination (Lys469/472), palmitoylation (Cys3/7/464/466), phosphorylation (Thr93/Ser237), and glycosylation (10 extracellular sites). These modifications govern its membrane localization, stability, and signal transduction capabilities.

CD36 plays a central role in atherosclerosis—a chronic inflammatory vascular disease—by mediating lipid metabolism, immune responses, and cellular dysfunction across multiple cell types, including endothelial cells, vascular smooth muscle cells (VSMCs), macrophages, and platelets. Rabbit anti-human CD36 antibodies serve as indispensable tools for exploring these multifaceted mechanisms and advancing therapeutic development for atherosclerosis.

2. Research Frontiers

Cutting-edge research has uncovered CD36’s pleiotropic roles in atherosclerosis, with key advancements in understanding its cell-specific functions and regulatory pathways. In endothelial cells, CD36 is upregulated by oxidized low-density lipoprotein (ox-LDL) and high-fat diets, mediating ox-LDL uptake and fatty acid metabolism to initiate subendothelial lipid accumulation—the earliest step in atherosclerotic lesion formation. Endothelial-specific CD36 knockout in mice reduces lipid deposition and improves metabolic homeostasis, validating its pathogenic role.

In VSMCs, CD36 signaling is activated by ox-LDL, promoting the expression of G-CSF/GM-CSF, enhancing cell migration to the intima, and driving neointima formation. Deficient CD36 in VSMCs suppresses proliferation and vascular remodeling. Macrophages rely on CD36 to uptake ox-LDL, transforming into foam cells—a hallmark of atherosclerotic plaques. This process is amplified by PPARγ-mediated CD36 upregulation, forming a pro-atherogenic positive feedback loop. CD36 also regulates macrophage polarization, metabolic reprogramming (glycolysis vs. oxidative phosphorylation), and pro-inflammatory cytokine release (TNF-α, IL-6).

Platelet CD36 contributes to thrombotic complications by promoting platelet activation via Src kinases and NADPH oxidase signaling, with elevated expression observed in coronary artery disease patients. Ongoing research explores CD36’s interaction with other scavenger receptors (e.g., LOX-1) and inflammatory pathways (e.g., NLRP3 inflammasome), as well as its potential as a therapeutic target for reversing atherosclerotic progression.

3. Research Significance

Research on CD36 in atherosclerosis holds profound implications for cardiovascular biology and clinical medicine. At the fundamental level, it reveals how a single scavenger receptor coordinates multiple pathogenic processes—lipid dysregulation, inflammation, and cellular dysfunction—across diverse vascular cell types. This integrated understanding provides a unifying framework for explaining atherosclerosis progression.

Clinically, CD36 represents a promising therapeutic target for atherosclerosis and its thrombotic complications. Targeting CD36 could inhibit foam cell formation, reduce vascular remodeling, and prevent thrombosis—addressing unmet needs for patients at high cardiovascular risk. Additionally, soluble CD36 and tissue-specific CD36 expression show potential as biomarkers for disease staging and risk stratification. Rabbit anti-human CD36 antibodies are critical for validating these biomarkers, elucidating cell-specific mechanisms, and accelerating the development of CD36-targeted drugs.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

CD36 drives atherosclerosis through cell-specific pathogenic pathways:

• Endothelial Dysfunction: CD36 mediates ox-LDL and fatty acid uptake, promoting subendothelial lipid accumulation and initiating early lesions. Fatty acid binding to CD36 enhances ox-LDL uptake via increased intracellular esterification, forming a pro-atherogenic feedback loop.
• VSMC Dysregulation: CD36 signaling induces G-CSF/GM-CSF expression and VSMC migration to the intima, driving neointima formation and vascular wall thickening. It also modulates VSMC proliferation and inflammatory responses.
• Macrophage Foam Cell Formation: CD36-dependent ox-LDL uptake activates PPARγ, further upregulating CD36 and promoting lipid accumulation. CD36 also triggers ROS production (NADPH oxidase), inflammasome activation (NLRP3), and pro-inflammatory cytokine release, exacerbating plaque inflammation.
• Platelet Activation: CD36 binds ox-LDL and advanced glycation end products, activating platelet signaling pathways to promote thrombosis—critical for atherosclerotic complications (e.g., myocardial infarction).

Research Methods

Exploring CD36’s roles in atherosclerosis relies on advanced cellular, molecular, and in vivo techniques, with rabbit anti-human CD36 antibodies as core tools:

• Immunohistochemistry/Western Blot: Detect CD36 expression in vascular tissues, cells, and patient samples to correlate with disease severity.
• Flow Cytometry: Quantify CD36 expression on immune cells (macrophages), platelets, and vascular cells from clinical samples and animal models.
• Co-Immunoprecipitation: Identify CD36-interacting proteins (e.g., PPARγ, Src kinases) to unravel signaling networks.
• Functional Assays: Measure ox-LDL uptake (lipid staining), cell migration/proliferation (transwell assays), cytokine release (ELISA), and platelet activation (aggregation assays) to assess CD36 modulation.
• Animal Models: Evaluate atherosclerosis progression in CD36 knockout or transgenic mice, using antibodies to validate CD36 expression and function.

Product Applications

ANT BIO PTE. LTD., via its sub-brand STARTER (specializing in antibodies), offers the high-performance Rabbit Anti-Human CD36 Antibody (Catalog Number: S0B5233)—a rigorously validated tool for atherosclerosis research. Developed using advanced antibody technology, this product exhibits exceptional specificity, affinity, and batch consistency, with validation across flow cytometry, Western Blot, and immunohistochemistry platforms.

Key application scenarios include:

• Atherosclerosis Mechanism Research: Investigate CD36’s role in lipid metabolism, foam cell formation, and vascular inflammation.
• Cell-Specific Function Studies: Characterize CD36 expression and activity in endothelial cells, VSMCs, macrophages, and platelets.
• Therapeutic Target Validation: Evaluate the efficacy of CD36 inhibitors/blockers in preclinical models of atherosclerosis.
• Biomarker Development: Detect soluble CD36 levels in patient plasma to explore its potential as a diagnostic or prognostic marker.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering global innovative pharmaceutical companies, research institutions, and life science researchers with high-quality biological reagents and comprehensive solutions. Leveraging state-of-the-art technology platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development systems (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—we strive to accelerate scientific discovery and translational research. Our sub-brands (Absin for general reagents and kits, STARTER for antibodies, and UA for recombinant proteins) synergize to address diverse research needs, contributing to breakthroughs in cardiovascular medicine, metabolic disease, and precision therapeutics. With certifications including EU 98/79/EC, ISO9001, and ISO13485, we uphold the highest standards of quality and reliability to support our mission of advancing human health through science.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.